These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 25156108)

  • 1. Molecular heterogeneity of glioblastoma and its clinical relevance.
    Eder K; Kalman B
    Pathol Oncol Res; 2014 Oct; 20(4):777-87. PubMed ID: 25156108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and cellular heterogeneity: the hallmark of glioblastoma.
    Aum DJ; Kim DH; Beaumont TL; Leuthardt EC; Dunn GP; Kim AH
    Neurosurg Focus; 2014 Dec; 37(6):E11. PubMed ID: 25434380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
    Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities.
    Maher EA; Brennan C; Wen PY; Durso L; Ligon KL; Richardson A; Khatry D; Feng B; Sinha R; Louis DN; Quackenbush J; Black PM; Chin L; DePinho RA
    Cancer Res; 2006 Dec; 66(23):11502-13. PubMed ID: 17114236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Subgroups of Glioblastoma- an Assessment by Immunohistochemical Markers.
    Nagy Á; Garzuly F; Padányi G; Szűcs I; Feldmann Á; Murnyák B; Hortobágyi T; Kálmán B
    Pathol Oncol Res; 2019 Jan; 25(1):21-31. PubMed ID: 28948518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma.
    Park AK; Kim P; Ballester LY; Esquenazi Y; Zhao Z
    Neuro Oncol; 2019 Jan; 21(1):59-70. PubMed ID: 30053126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Copy number profiling across glioblastoma populations has implications for clinical trial design.
    Cimino PJ; McFerrin L; Wirsching HG; Arora S; Bolouri H; Rabadan R; Weller M; Holland EC
    Neuro Oncol; 2018 Sep; 20(10):1368-1373. PubMed ID: 29982740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular biology of glioblastoma: Classification and mutational locations.
    Soomro SH; Ting LR; Qing YY; Ren M
    J Pak Med Assoc; 2017 Sep; 67(9):1410-1414. PubMed ID: 28924284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of glioblastoma (GBM) molecular classification methods.
    Lee E; Yong RL; Paddison P; Zhu J
    Semin Cancer Biol; 2018 Dec; 53():201-211. PubMed ID: 30031763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An integrative characterization of recurrent molecular aberrations in glioblastoma genomes.
    Sintupisut N; Liu PL; Yeang CH
    Nucleic Acids Res; 2013 Oct; 41(19):8803-21. PubMed ID: 23907387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic estimates of aneuploid content in glioblastoma multiforme and improved classification.
    Li B; Senbabaoglu Y; Peng W; Yang ML; Xu J; Li JZ
    Clin Cancer Res; 2012 Oct; 18(20):5595-605. PubMed ID: 22912392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequencing the next generation of glioblastomas.
    Jovčevska I
    Crit Rev Clin Lab Sci; 2018 Jun; 55(4):264-282. PubMed ID: 29668342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics.
    Li R; Chen X; You Y; Wang X; Liu Y; Hu Q; Yan W
    Oncotarget; 2015 Oct; 6(31):30968-74. PubMed ID: 26427041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas.
    Motomura K; Natsume A; Watanabe R; Ito I; Kato Y; Momota H; Nishikawa R; Mishima K; Nakasu Y; Abe T; Namba H; Nakazato Y; Tashiro H; Takeuchi I; Mori T; Wakabayashi T
    Cancer Sci; 2012 Oct; 103(10):1871-9. PubMed ID: 22747609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-cell RNA sequencing reveals the impact of chromosomal instability on glioblastoma cancer stem cells.
    Zhao Y; Carter R; Natarajan S; Varn FS; Compton DA; Gawad C; Cheng C; Godek KM
    BMC Med Genomics; 2019 May; 12(1):79. PubMed ID: 31151460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification.
    Wenger A; Ferreyra Vega S; Kling T; Bontell TO; Jakola AS; Carén H
    Neuro Oncol; 2019 May; 21(5):616-627. PubMed ID: 30668814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why is there a lack of consensus on molecular subgroups of glioblastoma? Understanding the nature of biological and statistical variability in glioblastoma expression data.
    Marko NF; Quackenbush J; Weil RJ
    PLoS One; 2011; 6(7):e20826. PubMed ID: 21829433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biobanking: An Important Resource for Precision Medicine in Glioblastoma.
    Tan SY; Sandanaraj E; Tang C; Ang BT
    Adv Exp Med Biol; 2016; 951():47-56. PubMed ID: 27837553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.
    Sottoriva A; Spiteri I; Piccirillo SG; Touloumis A; Collins VP; Marioni JC; Curtis C; Watts C; Tavaré S
    Proc Natl Acad Sci U S A; 2013 Mar; 110(10):4009-14. PubMed ID: 23412337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.